1. Intravenous buspirone for the prevention of postoperative nausea and vomiting

   • Peter Kranke
   • Kerstin D. Röhm
   • Martin R. Tramèr

   Clinical Trial 01 May 2012 Pages: 1465 - 1472

   

2. Relative bioavailability and pharmacodynamic effects of methantheline compared with atropine in healthy subjects

   • Christian Müller
   • Jörn Lötsch
   • Werner Siegmund

   Clinical Trial 21 April 2012 Pages: 1473 - 1481

   

3. Pharmacogenetics and healthcare outcomes in patients with chronic heart failure

   • Kye-Min Kim
   • Michael D. Murray
   • David A. Flockhart

   Pharmacogenetics 29 April 2012 Pages: 1483 - 1491

4. Association of UDP-glucuronosyltransferase 1A9 polymorphisms with adverse reactions to catechol-O-methyltransferase inhibitors in Parkinson’s disease patients

   • Marco Ferrari
   • Emilia Martignoni
   • Marco Cosentino

   Pharmacogenetics 15 April 2012 Pages: 1493 - 1499

5. Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment

   • Paul Statkevich
   • Teddy Kosoglou
   • David L. Cutler

   Pharmacokinetics and Disposition 19 April 2012 Pages: 1501 - 1508

   

6. Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin

   • Teddy Kosoglou
   • Yali Zhu
   • David L. Cutler

   Pharmacokinetics and Disposition 05 April 2012 Pages: 1509 - 1516

   

7. Population pharmacokinetics and Bayesian estimation of cyclosporine in a Tunisian population of hematopoietic stem cell transplant recipient

   • Hanene Eljebari
   • Emna Gaies
   • Anis Klouz

   Pharmacokinetics and Disposition 15 April 2012 Pages: 1517 - 1524

   

8. Exposure to medicines among patients admitted for hip fracture and the case-fatality rate at 1 year: a longitudinal study

   • A. Agustí
   • E. Pagès
   • J.-R. Laporte

   Pharmacoepidemiology and Prescription 15 April 2012 Pages: 1525 - 1531

   

9. Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study

   • Jean-Pascal Fournier
   • Agnès Sommet
   • Jean-Louis Montastruc

   Pharmacoepidemiology and Prescription 15 April 2012 Pages: 1533 - 1540

   

10. Paracetamol toxicity: what would be the implications of a change in UK treatment guidelines?

    • David J. McQuade
    • Paul I. Dargan
    • David M. Wood

    Pharmacoepidemiology and Prescription 19 April 2012 Pages: 1541 - 1547

11. Comparison of the effect of mesalazine and sulfasalazine on laboratory parameters: a retrospective observational study

    • Hideki Masuda
    • Yasuo Takahashi
    • Satoshi Asai

    Pharmacoepidemiology and Prescription 01 May 2012 Pages: 1549 - 1555

12. Bleeding adverse drug reactions (ADRs) in patients exposed to antiplatelet plus serotonin reuptake inhibitor drugs: analysis of the French Spontaneous Reporting Database for a controversial ADR

    • Franck Maschino
    • Caroline Hurault-Delarue
    • French Association of Regional Pharmacovigilance Centers

    Short Communication 15 April 2012 Pages: 1557 - 1560

13. CYP2C19 genetics in fatal carisoprodol intoxications

    • Gudrun Høiseth
    • Umair Majid
    • Espen Molden

    Short Communication 15 April 2012 Pages: 1561 - 1565

    

14. The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects

    • John Davis
    • Grant Langdon
    • Manoli Vourvahis

    Short Communication 22 April 2012 Pages: 1567 - 1572

    

15. Author reply to Fujimi et al

    • Richard A. Larson
    • Ophelia Q. P. Yin

    Letter to the Editors 04 April 2012 Pages: 1573 - 1574

16. Bile acid is important for gastrointestinal absorption of nilotinib

    • Akihito Fujimi
    • Naoto Takahashi
    • Kenichi Sawada

    Letter to the Editors 15 April 2012 Pages: 1575 - 1576